Levetiracetam Actavis

البلد: نيوزيلاندا

اللغة: الإنجليزية

المصدر: Medsafe (Medicines Safety Authority)

العنصر النشط:

Levetiracetam 500mg;  

متاح من:

Teva Pharma (New Zealand) Limited

INN (الاسم الدولي):

Levetiracetam 500 mg

جرعة:

500 mg

الشكل الصيدلاني:

Film coated tablet

تركيب:

Active: Levetiracetam 500mg   Excipient: Colloidal silicon dioxide Crospovidone Magnesium stearate Opadry yellow 85F32371 Povidone

نوع الوصفة الطبية :

Prescription

المصنعة من قبل:

Neuland Laboratories Limited

الخصائص العلاجية:

Use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation. Monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. Add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy (JME). Add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (IGE).

ملخص المنتج:

Package - Contents - Shelf Life: Blister pack, PVC/Al - 60 tablets - 36 months from date of manufacture stored at or below 25°C - Bottle, plastic, HDPE with LDPE screw cap and tamper evident - 100 tablets - 36 months from date of manufacture stored at or below 25°C

تاريخ الترخيص:

2015-01-22